HKSE:01558 (China)
Â
Ordinary Shares - Class H
HK$
12.86
(+0.47%)
Apr 29
Business Description
Yichang HEC ChangJiang Pharmaceutical Co Ltd
ISIN : CNE1000023R6
Share Class Description:
HKSE:01558: Ordinary Shares - Class HCompare
Compare
Traded in other countries / regions
01558.Hong KongYIHCF.USA IPO Date
2015-12-29Description
Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.65 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.33 | |||||
| Debt-to-EBITDA | 1.11 | |||||
| Interest Coverage | 12.65 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 1.45 | |||||
| Beneish M-Score | -1.44 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.5 | |||||
| 3-Year EBITDA Growth Rate | -32 | |||||
| 3-Year EPS without NRI Growth Rate | -35.6 | |||||
| 3-Year FCF Growth Rate | 100.2 | |||||
| 3-Year Book Growth Rate | 11 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.4 | |||||
| 9-Day RSI | 67.41 | |||||
| 14-Day RSI | 65.82 | |||||
| 6-1 Month Momentum % | 56.88 | |||||
| 12-1 Month Momentum % | 58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.4 | |||||
| Quick Ratio | 1.3 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 100.79 | |||||
| Days Sales Outstanding | 80.03 | |||||
| Days Payable | 51.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.7 | |||||
| Shareholder Yield % | -4.83 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.21 | |||||
| Operating Margin % | 45.72 | |||||
| Net Margin % | 31.66 | |||||
| FCF Margin % | 34.21 | |||||
| ROE % | 28.66 | |||||
| ROA % | 15.6 | |||||
| ROIC % | 22.24 | |||||
| ROC (Joel Greenblatt) % | 42.48 | |||||
| ROCE % | 30.32 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 5.2 | |||||
| PE Ratio without NRI | 4.14 | |||||
| PS Ratio | 1.63 | |||||
| PB Ratio | 1.3 | |||||
| Price-to-Tangible-Book | 1.93 | |||||
| Price-to-Free-Cash-Flow | 4.82 | |||||
| Price-to-Operating-Cash-Flow | 3.69 | |||||
| EV-to-EBIT | 4.78 | |||||
| EV-to-EBITDA | 4.78 | |||||
| EV-to-Revenue | 1.79 | |||||
| EV-to-FCF | 5.2 | |||||
| Price-to-Projected-FCF | 3.16 | |||||
| Price-to-Graham-Number | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 8.3 | |||||
| Earnings Yield (Greenblatt) % | 20.92 | |||||
| FCF Yield % | 20.81 | |||||
| Forward Rate of Return (Yacktman) % | 19.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Yichang HEC ChangJiang Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 6,884.89 | ||
| EPS (TTM) (HK$) | 2.472 | ||
| Beta | 1.11 | ||
| Volatility % | 42.9 | ||
| 14-Day RSI | 65.82 | ||
| 14-Day ATR (HK$) | 0.461514 | ||
| 20-Day SMA (HK$) | 12.026 | ||
| 12-1 Month Momentum % | 58 | ||
| 52-Week Range (HK$) | 6.02 - 13.3 | ||
| Shares Outstanding (Mil) | 879.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Yichang HEC ChangJiang Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Yichang HEC ChangJiang Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Yichang HEC ChangJiang Pharmaceutical Co Ltd Frequently Asked Questions
What is Yichang HEC ChangJiang Pharmaceutical Co Ltd(HKSE:01558)'s stock price today?
The current price of HKSE:01558 is HK$12.86. The 52 week high of HKSE:01558 is HK$13.30 and 52 week low is HK$6.02.
When is next earnings date of Yichang HEC ChangJiang Pharmaceutical Co Ltd(HKSE:01558)?
The next earnings date of Yichang HEC ChangJiang Pharmaceutical Co Ltd(HKSE:01558) is .
Does Yichang HEC ChangJiang Pharmaceutical Co Ltd(HKSE:01558) pay dividends? If so, how much?
Yichang HEC ChangJiang Pharmaceutical Co Ltd(HKSE:01558) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers